Phaseline

Companies › Windtree Therapeutics

Windtree Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Cardiovascular.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Istaroxime
Sodium/potassium-transporting ATPase inhibitor; Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 activator
Na+/K+-ATPase, ATP1B2, ATP1B1, ATP1B3, FXYD2Phase 1Cardiogenic Shock–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05975021IstaroximePhase 1Cardiogenic ShockCardiovascularJul 2025

From the company's SEC filings

Cash of $0m on 2025-09-30; operating cash outflow about $15m a year; runway about 0 months at that burn, to Oct 2025

Agreements filed with the SEC (item 1.01), last two years

Targets

Na+/K+-ATPase (1) ATP1B2 (1) ATP1B1 (1) ATP1B3 (1) FXYD2 (1)

Companies with the same targets

Seismic Pharmaceuticals Operations

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.